Advertisement

Etoposid in der Behandlung des inoperablen Bronchuskarzinoms

  • H. Hausmaninger

Zusammenfassung

Das Bronchuskarzinom ist in der Krebsinzidenz mit 22% nach wie vor die häufigste bösartige Neubildung des Mannes, jedoch ist auch bei Frauen ein beträchtlicher Anstieg in der Häufigkeit der Neuerkrankungen festzustellen — 1981 waren in den U.S.A. 8% aller Neoplasien bei Frauen Bronchuskarzinome (1).

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Silverberg, E: Cancer Statistics. American Cancer Society. 1981.Google Scholar
  2. 2.
    Carter, S. K., et al: Chemotherapy of cancer, S. 193–199. New York- London-Sydney-Toronto: Wiley Medical Publication. 1977.Google Scholar
  3. 3.
    Katlic, M., Carter, D: Prognostic implication of histology, size and location of primary tumors. In: Lung Cancer: Progress in Therapeutic Research (Muggia, F., Rozencweig, M., Hrsg.), S. 143–150. New York: Raven Press. 1979.Google Scholar
  4. 4.
    Kreyberg, L: Histologie typing of lung tumours. Geneva: World Health Organization. 1967.Google Scholar
  5. 5.
    Monfardini, S., et al: Manual of cancer chemotherapy, 3. Aufl., S. 123–127. Geneva: UICC. 1981.Google Scholar
  6. 6.
    Nissen, I., et al: Clinical trial of VP16–213 i.v. twice weekly in advanced neoplastic disease. Cancer 45, 232–235 (1980).PubMedCrossRefGoogle Scholar
  7. 7.
    Itri, L., et al: Phase II trial of VP 16-213 in non-small cell lung cancer (NSCLC). Cancer Clinical Trials 1981.Google Scholar
  8. 8.
    Falkson, G., et al: A clinical trial of the oral form of 4’-demethylepipodo- phyllotoxin-ß-D-ethylidene glucoside. Cancer 35, 1141–1144 (1975).PubMedCrossRefGoogle Scholar
  9. 9.
    Eagan, R., et al: VP 16-213 chemotherapy for advanced squamous cell and adenocarcinoma of the lung. Cancer Treat. Rep. 62, 843–844 (1978).Google Scholar
  10. 10.
    Cavalli, F., et al: A combination of cyclophosphamide, methotrexate, vincristine and VP 16-213 (NSC 141540) in the treatment of bronchogenic carcinoma. Tumori 63, 169–173 (1977).PubMedGoogle Scholar
  11. 11.
    Eagan, R., et al: Cyclophosphamide and VP16 with or without cisplatinum in squamous cell and small cell lung cancer. Cancer Treat. Rep. 65, 453–458 (1981).Google Scholar
  12. 12.
    Morasca, L., et al: VP 16-213 and cyclophosphamide in non oat cell bronchogenic carcinoma. First Internat. Symposium on the Podophylloto- xins in Cancer Therapy. Southampton, England, 8. und 9. Juli 1981.Google Scholar
  13. 13.
    Schilcher, R. B., et al: Ifosfamide and VP 16-213 combination chemotherapy in inoperable bronchogenic carcinoma. Abstracts of the Fifth Annual Meeting of the Medical Oncology Society, Nice, France, 1. bis 3. Dezember 1979, S. 43. Berlin-Heidelberg-New York: Springer. 1979.Google Scholar
  14. 14.
    Mabel, J. A., et al: Therapeutic synergism in murine tumours for combi- nations of cisplatinum with VP 16-213 or BCNU. Proc. AACR and ASCO 20, 230 (1979).Google Scholar
  15. 15.
    Dhingra, H. M., et al: Phase II clinical study of cis-dichlorodiamminepla- tinum (CCDP) and VP 16-213 (VP16) in combination for patients (PTS) with extensive non-small cell lung cancer (E-NSCLC). Proc. AACR and ASCO 22, 200 (1981).Google Scholar
  16. 16.
    Mitrou, P. S., et al: Behandlungsergebnisse mit VP 16-213 und Cisplatinum bei inoperablen nichtkleinzelligen Bronchuskarzinomen. Etopo- sid-Symposium, Frankfurt/Main, Mai 1981.Google Scholar
  17. 17.
    Cavalli, F., Joss, R: Cisplatinum and etoposide (DDP/VP 16-213) in the treatment of non-small cell lung cancer. Proceedings International Symposium, New Drugs for Cancer Therapy in the Eighties, Rome 1981.Google Scholar
  18. 18.
    Klastersky, J., et al: Therapy with cisplatinum and etoposide in bronchogenic squamous cell cancer and adenocarcinoma. Proceedings of International Symposium, New Drugs for Cancer Therapy in the Eighties, Rome 1981.Google Scholar
  19. 19.
    Gralla, R. J., et al: Cisplatinum and Vindesine combination chemotherapy for advanced Carcinoma of the lung: A randomized trial investi- gating two dosage schedules. Ann. Int. Med. 95, 414–420 (1981).PubMedGoogle Scholar
  20. 20.
    Hyde, L., et al: Cell type and the natural history of lung cancer. JAMA 193, 140–142 (1965).CrossRefGoogle Scholar
  21. 21.
    Brunner, K. W., et al: Comparison of the biologic activity of VP 16-213 given i.v. and orally in capsules or drink ampules. Cancer Treat. Rep. 60, 1377–1379 (1976).PubMedGoogle Scholar
  22. 22.
    Klastersky, J., et al: Cisplatinum, ADM and etoposide (CAV) for remission induction of small-cell bronchogenic Carcinoma: evaluation of efficacy and toxicity and pilot study of a “late intensification” with autologous bone-marrow rescue. Cancer 50 (4), 652–658 (1982).PubMedCrossRefGoogle Scholar
  23. 23.
    Aisner, J., et al: Doxorubicin, cyclophosphamide and VP 16-213 (ACE) in the treatment of small cell lung cancer. Cancer Chemother. Pharmacol. 7 (2/3), 187–193 (1982).Google Scholar
  24. 24.
    Aisner, J., et al: Combination chemotherapy for small cell carcinoma of the lung: continuous versus alternating non-cross-resistant combinations. Cancer Treat. Rep. 66 (2), 221–230 (1982).PubMedGoogle Scholar
  25. 25.
    Abeloff, M. D., et al: Intensive induction chemotherapy in 54 patients with small cell carcinoma of the lung. Cancer Treat. Rep. 65 (7–8), 639–646 (1981).PubMedGoogle Scholar
  26. 26.
    Aroney, R. S., et al: Alternating non-cross-resistant combination chemotherapy for small cell anaplastic carcinoma of the lung. Cancer 49 (12), 2449–2454 (1982).PubMedCrossRefGoogle Scholar
  27. 27.
    Sierocki, J. S., et al: Cis-dichlorodiammineplatinum (II) and VP 16-213: An active induction regimen for small cell carcinoma of the lung. Cancer Treat. Rep. 63, 1593–1597 (1979).PubMedGoogle Scholar
  28. 28.
    Linninger, T. R., et al: Evaluation of alternating chemotherapy and sites and extent of disease in extensive small cell lung cancer. Cancer 48, 2147–2153 (1981).CrossRefGoogle Scholar

Copyright information

© Springer-Verlag/Wien 1984

Authors and Affiliations

  • H. Hausmaninger
    • 1
  1. 1.1. Medizinische AbteilungLandeskrankenanstaltenDeutschland

Personalised recommendations